Skin IaM: An Exploratory Clinical Trial to Evaluate Changes in Skin Appearance, Colour, and/or Texture Following the Induction of a Local Inflammatory Skin Response

Exclusion Criteria

• •Male aged \< 25 years or \>40 years.
• •Female of any age.
• •Tattoos on or within 5 cm of the area to be assessed.
• •Scars on or with 5 cm of the area to be assessed.
• •Current, active inflammatory skin disease, or past history of any inflammatory skin disease (other than acne) such as psoriasis, atopic dermatitis.
• •Suffered from any significant allergies (i.e. food, environmental, contact).
• •Subjects who are immunocompromised (i.e. HIV positive, Hepatitis C, transplant, etc.), based on clinical history.
• •Subjects who currently have an activated immune system (e.g from current infection or recent vaccination).
• •Subjects who have a history of chronic disease such as diabetes.
• •Use of investigational therapy in the preceding month prior to screening visit.
• •Use of G-CSF, GM-CSF, IL-2, IFNs, erythropoietin, systemic or inhaled steroids within one month of the screening visit.
• •Use of oral analgesics/anti-inflammatories (e.g. paracetamol, ibuprofen, aspirin, codeine) or topical anti-inflammatories (e.g., ibuprofen) within 5 days of the screening visit.
• •Concurrent disease or conditions that may present a risk to the subjects.